Cardiac Amyloidosis

With the first drug treatments for cardiac amyloidosis recently entering the market, there has been an explosion of interest to diagnose and care for these patients. It is considered a rare disease, but many experts now say it is actually just be under diagnosed. The disease is caused by protein misfolding. Normally soluble proteins in the bloodstream become insoluble and deposit abnormally in the tissues and organs throughout the body. There are three main kinds of amyloid that affect the heart, light chain amyloid (AL) and two types of transthyretin amyloid (ATTR or TTR). The first type of ATTR is hereditary, or familial amyloid, and the second is wild type, or age-related TTR amyloid. Nuclear imaging, echocardiography, CT and MRI all play roles in diagnosing amyloid and in determining the subtype, which is required for targeted treatment. 

RSS icon
Stephen Little, MD, discusses trends in echocardiography at ASE 2023. #ASE23 #ASE2023 What is new in cardiac ultrasound.

Back in the spotlight: Exploring echocardiography's revival

American Society of Echocardiography President Stephen Little, MD, says several trends and technologies are coming together at once, leading to renewed interest in echo.

VIDEO: American Society of Nuclear Cardiology (ASNC) President Mouaz Al-Mallah, MD, chair of cardiovascular PET and associate director of nuclear cardiology, Houston Methodist DeBakey Heart and Vascular Center, and ASNC President-elect Larry Phillips, MD, director of nuclear cardiology, NYU Langone, outline the new technologies available and why upgrading cardiac nuclear labs matters and what is the ROI. #ASNC

What is the ROI for upgrading nuclear cardiology labs?

Some nuclear cardiology labs are still using SPECT systems that are 20-25 years old. Is it time to make an upgrade? 

cardiac amyloidosis on bone scan

Cardiac amyloidosis becoming less rare thanks to nuclear medicine studies

A new study in the Journal of Nuclear Medicine offers insight into how the condition affects the general population, as well as how radiologists can help in the cardiac amyloidosis diagnostic journey.

Attralus completes financing to validate pan-amyloid nuclear imaging agent

Biopharmaceutical firm Attralus has completed a $25 million Series A financing designed to further validate its AT-01 pan-amyloid radiotracer for PET/CT.

Thumbnail

ASNC publishes new amyloidosis imaging guidelines

“We anticipate that these expert multisocietal consensus recommendations on multimodality imaging in cardiac amyloidosis will standardize the diagnosis and improve the management of this highly morbid and underdiagnosed disease," wrote authors of the new guidelines published in the Journal of Nuclear Cardiology.

Image reconstruction algorithm, MRI-derived heart strain values can aid prognosis in amyloidosis patients

Recent research found strain parameters taken from a cine MRI-based deformable registration algorithm (DRA) can determine the severity of amyloid buildup in the heart and may provide prognostic information on patients with light-chain (AL) amyloidosis.

SNMMI: Scanning for cardiac amyloid could help predict heart attacks

While amyloid imaging is typically discussed with regard to diagnosing Alzheimer’s disease, a team of French researchers, presenting at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2015 annual meeting, have found that amyloid scans of the heart can predict major cardiac events.

Thumbnail

PET technique visualizes amyloid deposits in heart

PET with 11C-PIB provides a noninvasive method for visualizing amyloid deposits in the heart, according to a study published in the February issue of the Journal of Nuclear Medicine. The researchers suggest that 11C-PIB eventually may be used in the clinical setting as both a diagnostic tool and a treatment follow-up method.

Displaying 9 - 16 of 16

Around the web

Cardiovascular Business
Cardiology, radiology specialists debate CCTA’s rise as a go-to imaging modality for CAD

CCTA is being utilized more and more for the diagnosis and management of suspected coronary artery disease. An international group of specialists shared their perspective on this ongoing trend.

Cardiovascular Business
New AI program delivers rapid, accurate echo video assessments

The new technology shows early potential to make a significant impact on imaging workflows and patient care. 

Radiology Business
Key Medicare reimbursement and No Surprises Act updates from RSNA 2024

Richard Heller III, MD, RSNA board member and senior VP of policy at Radiology Partners, offers an overview of policies in Congress that are directly impacting imaging.